

Qi Pei

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9622091/publications.pdf>

Version: 2024-02-01

41
papers

431
citations

933447

10
h-index

839539

18
g-index

42
all docs

42
docs citations

42
times ranked

513
citing authors

#	ARTICLE	IF	CITATIONS
1	Prediction of pharmacokinetic parameters of inhaled indacaterol formulation in healthy volunteers using physiologically-based pharmacokinetic (PBPK) model. <i>European Journal of Pharmaceutical Sciences</i> , 2022, 168, 106055.	4.0	3
2	Open-Label, Phase I, Pharmacokinetic Studies in Healthy Chinese Subjects to Evaluate the Bioequivalence and Food Effect of a Novel Formulation of Abiraterone Acetate Tablets. <i>Drug Design, Development and Therapy</i> , 2022, Volume 16, 3-12.	4.3	3
3	Population pharmacokinetics of omeprazole in obese and normal-weight adults. <i>Expert Review of Clinical Pharmacology</i> , 2022, 15, 461-471.	3.1	5
4	External Evaluation of Population Pharmacokinetic Models to Inform Precision Dosing of Meropenem in Critically Ill Patients. <i>Frontiers in Pharmacology</i> , 2022, 13, .	3.5	8
5	Population Pharmacokinetics-Based Approach to Drug Dosing Adherence. <i>Clinical Pharmacology and Therapeutics</i> , 2021, 110, 23-23.	4.7	0
6	Bioequivalence and Pharmacokinetic Profiles of Generic and Branded Obeticholic Acid in Healthy Chinese Subjects Under Fasting and Fed Conditions. <i>Drug Design, Development and Therapy</i> , 2021, Volume 15, 185-193.	4.3	4
7	External evaluation of published population pharmacokinetic models of polymyxin B. <i>European Journal of Clinical Pharmacology</i> , 2021, 77, 1909-1917.	1.9	11
8	The pharmacokinetic challenge of polymyxin B in critically ill patients with morbid obesity. <i>Journal of Global Antimicrobial Resistance</i> , 2021, 27, 172-174.	2.2	1
9	Effect of laparoscopic sleeve gastrectomy on drug pharmacokinetics. <i>Expert Review of Clinical Pharmacology</i> , 2021, 14, 1481-1495.	3.1	5
10	Study on Pharmacokinetic Interactions Between HS-10234 and Emtricitabine in Healthy Subjects: An Open-Label, Two-Sequence, Self-Controlled Phase I Trial. <i>Infectious Diseases and Therapy</i> , 2021, , 1.	4.0	1
11	Effect of CYP4F2 Polymorphisms on Ticagrelor Pharmacokinetics in Healthy Chinese Volunteers. <i>Frontiers in Pharmacology</i> , 2021, 12, 797278.	3.5	5
12	A randomized, double-blind, single-dose study to evaluate the biosimilarity of QL1101 with bevacizumab in healthy male subjects. <i>Cancer Chemotherapy and Pharmacology</i> , 2020, 85, 555-562.	2.3	12
13	Response by Pei et al. to letters regarding article, "Pharmacokinetic study of imrecoxib in patients with renal insufficiency"; <i>European Journal of Clinical Pharmacology</i> , 2020, 76, 473-474.	1.9	0
14	Quality of oral anticoagulation control in Chinese patients with non-valvular atrial fibrillation: a prospective controlled study. <i>Current Medical Research and Opinion</i> , 2020, 36, 1433-1439.	1.9	5
15	Effect of high-fat diet on the pharmacokinetics and safety of flumatinib in healthy Chinese subjects. <i>Cancer Chemotherapy and Pharmacology</i> , 2020, 86, 339-346.	2.3	4
16	The response-time relationship and covariate effects of acupuncture for chronic pain: A systematic review and model-based longitudinal meta-analysis. <i>European Journal of Pain</i> , 2020, 24, 1653-1665.	2.8	11
17	First-in-human, phase I single-ascending-dose study of the safety, pharmacokinetics, and relative bioavailability of selatinib, a dual EGFR-ErbB2 inhibitor in healthy subjects. <i>Investigational New Drugs</i> , 2020, 38, 1826-1835.	2.6	1
18	Genotype-Guided Dosing of Warfarin in Chinese Adults. <i>Circulation Genomic and Precision Medicine</i> , 2020, 13, e002602.	3.6	13

#	ARTICLE	IF	CITATIONS
19	Dose investigation of imrecoxib in patients with renal insufficiency based on modelling and simulation. <i>European Journal of Pharmaceutical Sciences</i> , 2020, 152, 105449.	4.0	3
20	Bioequivalence studies of inhaled indacaterol maleate in healthy Chinese volunteers under gastrointestinal non-blocking or blocking with concomitant charcoal administration. <i>Pulmonary Pharmacology and Therapeutics</i> , 2020, 61, 101902.	2.6	2
21	Effect of postdose fasting duration on hetrombopag olamine pharmacokinetics and pharmacodynamics in healthy volunteers. <i>British Journal of Clinical Pharmacology</i> , 2020, 86, 1528-1536.	2.4	18
22	Exploration of suitable pharmacodynamic parameters for acarbose bioequivalence evaluation: A series of clinical trials with branded acarbose. <i>British Journal of Clinical Pharmacology</i> , 2020, 86, 2225-2233.	2.4	4
23	Bazedoxifene Plays a Protective Role against Inflammatory Injury of Endothelial Cells by Targeting CD40. <i>Cardiovascular Therapeutics</i> , 2020, 2020, 1-12.	2.5	6
24	Pharmacokinetic study of imrecoxib in patients with renal insufficiency. <i>European Journal of Clinical Pharmacology</i> , 2019, 75, 1355-1360.	1.9	9
25	Effects of UGT1A1 Polymorphism, Gender and Triglyceride on the Pharmacokinetics of Telmisartan in Chinese Patients with Hypertension: A Population Pharmacokinetic Analysis. <i>European Journal of Drug Metabolism and Pharmacokinetics</i> , 2019, 44, 797-806.	1.6	5
26	Phase I Trial of Pyragrel, a Novel Thromboxane Synthetase Inhibitor, to Evaluate the Safety, Tolerability, and Pharmacokinetics in Healthy Volunteers. <i>Frontiers in Pharmacology</i> , 2019, 10, 1231.	3.5	0
27	<p>Pharmacokinetics and Safety of Esketamine in Chinese Patients Undergoing Painless Gastroscopy in Comparison with Ketamine: A Randomized, Open-Label Clinical Study</p>. <i>Drug Design, Development and Therapy</i> , 2019, Volume 13, 4135-4144.	4.3	105
28	Simultaneous determination of Pyragrel, a novel anti-thrombotic agent, and its two primary metabolites in plasma by HPLC<sup>MS/MS. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2018, 156, 199-205.	2.8	5
29	Repaglinide-irbesartan drug interaction: effects of SLCO1B1 polymorphism on repaglinide pharmacokinetics and pharmacodynamics in Chinese population. <i>European Journal of Clinical Pharmacology</i> , 2018, 74, 1021-1028.	1.9	8
30	Influences of CYP2D6*10 polymorphisms on the pharmacokinetics of iloperidone and its metabolites in Chinese patients with schizophrenia: a population pharmacokinetic analysis. <i>Acta Pharmacologica Sinica</i> , 2016, 37, 1499-1508.	6.1	9
31	Genetic polymorphisms of Wnt/β ² -catenin pathway genes are associated with the efficacy and toxicities of radiotherapy in patients with nasopharyngeal carcinoma. <i>Oncotarget</i> , 2016, 7, 82528-82537.	1.8	26
32	Simultaneous Determination of Trantinterol and One of Its Major Metabolites, 1-Carbonyl Trantinterol, in Human Plasma by LC<sup>MS-MS. <i>Journal of Chromatographic Science</i> , 2015, 53, 1303-1309.	1.4	0
33	Marked Alteration of Rosuvastatin Pharmacokinetics in Healthy Chinese with ABCG2 34G>A and 421C>A Homozygote or Compound Heterozygote. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2015, 354, 310-315.	2.5	36
34	Cytochrome P450 2D6*10 genotype affects the pharmacokinetics of dimemorfan in healthy Chinese subjects. <i>European Journal of Drug Metabolism and Pharmacokinetics</i> , 2015, 40, 427-433.	1.6	3
35	Evaluation of the Highly Variable Agomelatine Pharmacokinetics in Chinese Healthy Subjects to Support Bioequivalence Study. <i>PLoS ONE</i> , 2014, 9, e109300.	2.5	11
36	Pharmacokinetics and Tissue Distribution Study of Chlorogenic Acid from <i>Lonicerae Japonicae Flos</i> Following Oral Administrations in Rats. <i>Evidence-based Complementary and Alternative Medicine</i> , 2014, 2014, 1-7.	1.2	15

#	ARTICLE	IF	CITATIONS
37	Development and validation of an LC-MS/MS method for the determination of tolvaptan in human plasma and its application to a pharmacokinetic study. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2013, 913-914, 84-89.	2.3	18
38	PPAR- β 2 and PTPRD gene polymorphisms influence type 2 diabetes patients' response to pioglitazone in China. <i>Acta Pharmacologica Sinica</i> , 2013, 34, 255-261.	6.1	50
39	LC-MS-MS Quantitative Determination of Brivudine in Human Plasma and Its Application to Pharmacokinetic Studies. <i>Chromatographia</i> , 2011, 73, 1089-1095.	1.3	3
40	Population Pharmacokinetic Evaluation with External Validation of Tacrolimus in Chinese Primary Nephrotic Syndrome Patients. <i>Pharmaceutical Research</i> , 0, , .	3.5	1
41	Population Pharmacokinetic Modelling for Nifedipine to Evaluate the Effect of Parathyroid Hormone on CYP3A in Patients with Chronic Kidney Disease. <i>Drug Design, Development and Therapy</i> , 0, Volume 16, 2261-2274.	4.3	1